Compare BLMN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLMN | KROS |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 584.9M |
| IPO Year | 2012 | 2020 |
| Metric | BLMN | KROS |
|---|---|---|
| Price | $6.23 | $16.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $8.50 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 2.4M | 266.1K |
| Earning Date | 02-25-2026 | 03-03-2026 |
| Dividend Yield | ★ 7.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | ★ $3,952,793,000.00 | $246,718,000.00 |
| Revenue This Year | $2.19 | $6,924.79 |
| Revenue Next Year | $0.35 | N/A |
| P/E Ratio | $16.77 | ★ $10.53 |
| Revenue Growth | 7.72 | ★ 37798.31 |
| 52 Week Low | $5.86 | $9.12 |
| 52 Week High | $12.47 | $22.55 |
| Indicator | BLMN | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 36.19 |
| Support Level | $6.37 | $16.31 |
| Resistance Level | $7.36 | $17.17 |
| Average True Range (ATR) | 0.39 | 0.63 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 44.00 | 18.26 |
Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabba's. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S., while restaurants operating outside the U.S. are included in the international segment.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.